South San Francisco, California April 30, 2024–(BUSINESS WIRE)–Incitro, a machine learning-powered drug discovery and development company, today announced the appointment of Dr. Emily Fox as Senior Vice President of AI/Machine Learning. In this role, she will oversee these areas as well as data science and computational biology, including data modalities across genetics, omics, imaging, clinical data, and molecular design. Dr. Fox, a professor in the Department of Statistics and Department of Computer Science at Stanford University, said her pioneering research has had a direct impact on patients and has made groundbreaking contributions in the application of machine learning in medicine. I've been doing it.
“AI leaders with Emily's ability to simultaneously understand biology and health are rare, and we are thrilled to have her lead our AI/ML team,” said Daphne Kohler, Ph.D., co-founder and CEO. I am honored to have done so.” “Her groundbreaking work in machine learning, along with her track record of translating research into impactful applications in the medical field, supports our mission to revolutionize drug discovery through a data-driven approach. Emily's outstanding track record in innovation and leadership has been recognized with prestigious awards and awards that celebrate her exceptional contributions to the field and her wealth of knowledge. We are excited to welcome this visionary to the insitro team.”
“The transformative power of machine learning in redefining biology is increasingly recognized, and insitro is leveraging this by seamlessly integrating vast biological and clinical datasets with cutting-edge machine learning techniques. “We are uniquely positioned to apply this potential to improving human health, providing insights not previously revealed,” Dr. Fox said. “These insights will be transformative in accelerating the discovery of new targets and the development of molecules that interact with them, ushering in a new era of therapeutic innovation. As someone who's passionate about machine learning, it's really inspiring to be part of a company that does machine learning, where learning is a core part of the mission, and it's built into the entire pipeline from data collection to scientific discovery to drug discovery. is.”
Prior to joining Stanford University, Dr. Fox founded, grew, and led the Health AI team at Apple, where he was a Distinguished Engineer. At Apple, her team collaborates cross-functionally on health and wellness projects that leverage Apple's ecosystem of devices and software, and partners such as Aetna, Johnson & Johnson, Eli Lilly, and Seattle Influenza Research. We also conducted research with. She also served as Amazon Professor of Machine Learning in the Paul G. Allen School of Computer Science & Engineering and Department of Statistics at the University of Washington. Her academic research focuses on discovering interpretable latent structures from complex, high-dimensional scientific and clinical datasets, and data arising in genomics and neuroscience, as well as wearable devices and other medical applications. Focuses on machine learning for medical applications, including application use. Wild sensing modalities.
Her work was recognized by being selected as a CZ Biohub – San Francisco Investigator (2022-2027) and co-chairing the NeurIPS program in 2019. She is also a recipient of the Presidential Early Career Award for Scientists and Engineers (PECASE). She received the Sloan Research Fellowship, the ONR Young Investigator Award, and the NSF CAREER Award. This dissertation was recognized as a recipient of the Leonard J. Savage Dissertation Award in Applied Methodology and the MIT EECS Jin O Cong Outstanding Dissertation Award.
Fei-Fei Li, AI pioneer, Sequoia Professor of Computer Science, and founding co-director of Stanford University's Institute for Human-Centered AI, said, “I knew both Emily Fox and Daphne Kohler and had many I have had the privilege of working with such people.” Over the years, I have witnessed their decisive contributions to machine learning, especially in healthcare. With Emily joining his insitro, their joint efforts to leverage his AI for biological discovery and drug discovery will revolutionize the field. Leveraging diversity of thought in AI to drive not only technological progress but also social improvement. ”
About Incitro
insitro is a drug discovery and development company that applies machine learning (ML) and generative AI to large-scale data to decipher the biology of innovative medicines. The core of the insitro approach is the convergence of in-house generated multimodal cellular data and high-content phenotypic human cohort data. These data are used to develop ML models that extend insitro data tensors through imputation, reveal underlying biological conditions, and elucidate genetic regulators that significantly impact disease. These powerful models rely on extensive biological and computational infrastructure to advance new targets and patient biomarkers in-situ, design treatments, and inform clinical strategies. enable you to provide. insitro powers a wholly owned and partnered pipeline of insights and therapeutics in neuroscience, oncology, and metabolism. Since its founding in 2018, Incitro has raised over $700 million in funding through partnerships with top technology, biotech, crossover investors and pharmaceutical partners. For more information about insitro, please visit www.insitro.com.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240430325635/ja/
contact address
media contact
Dan Budwick
dan@1abmedia.com
Company contact information
Eric McKeevey
communication advisor
eric@insitro.com
